GlassScriptPhysician profile
Stephanie L Koonce
NPI 1609035807
$3,631.33
in general payments reported to CMS, 2019-2025
43 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $998 · 2023: $862 · 2024: $129 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.97 |
| Education | $219.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $455.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.43 | 2021-2025 | Calquence, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $298.09 | 2021-2025 | Rybrevant, Darzalex, Talvey |
| Pfizer INC. | $244.48 | 2021-2025 | |
| Celgene Corporation | $227.11 | 2022-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $208.00 | 2021-2025 | Opdivo, Reblozyl |
| Merck Sharp & Dohme LLC | $181.67 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $172.30 | 2021-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $140.58 | 2022-2025 | Retevmo, Jaypirca, Verzenio |
| Seagen INC. | $117.22 | 2023-2025 | Adcetris |
| Eisai INC. | $104.00 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $103.06 | 2022-2023 | Imbruvica |
| Incyte Corporation | $101.70 | 2021-2025 | Niktimvo, Jakafi |
| Emd Serono, INC. | $93.65 | 2021-2024 | |
| Genentech USA, INC. | $78.04 | 2023-2025 | Alecensa, Tecentriq, Itovebi |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Koonce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.